US 11,866,466 B2
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
Natalie Winblade Nairn, Seattle, WA (US); Julia Novak, Sequim, WA (US); Kenneth Grabstein, Mercer Island, WA (US); Dennis Miller, Woodinville, WA (US); Greg T. Hermanson, Loves Park, IL (US); Scott R. Presnell, Tacoma, WA (US); and Mark Stroud, Seattle, WA (US)
Assigned to BLAZE BIOSCIENCE, INC., Seattle, WA (US)
Appl. No. 16/954,190
Filed by BLAZE BIOSCIENCE, INC., Seattle, WA (US)
PCT Filed Dec. 18, 2018, PCT No. PCT/US2018/066337
§ 371(c)(1), (2) Date Jun. 15, 2020,
PCT Pub. No. WO2019/126240, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/622,711, filed on Jan. 26, 2018.
Claims priority of provisional application 62/607,893, filed on Dec. 19, 2017.
Prior Publication US 2021/0130419 A1, May 6, 2021
Int. Cl. A61K 38/00 (2006.01); C07K 14/435 (2006.01); A61K 47/65 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 19/00 (2006.01)
CPC C07K 14/43522 (2013.01) [A61K 45/06 (2013.01); A61K 47/64 (2017.08); A61K 47/65 (2017.08); A61P 35/00 (2018.01); C07K 19/00 (2013.01)] 22 Claims
 
1. A composition comprising a peptide-immuno-oncology agent complex, the peptide-immuno-oncology agent complex comprising a peptide complexed with an immuno-oncology agent, wherein the peptide of the peptide-immuno-oncology agent complex comprises:
at least 4 cysteine residues, and
a plurality of disulfide bridges formed between the cysteine residues;
wherein the peptide is tumor-homing,
wherein the immuno-oncology agent comprises an IL-15 agent, and
wherein the peptide-immuno-oncology agent complex comprises:
a) SEQ ID NO: 1330;
b) SEQ ID NO: 1340; or
c) any one of SEQ ID NO: 1317, SEQ ID NO: 1328, SEQ ID NO: 1435, SEQ ID NO: 1437, or SEQ ID NO: 1441.